Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys
Cell, Volume 185, No. 25, Year 2022
Notification
URL copied to clipboard!
Description
Pediatric SARS-CoV-2 vaccines are needed that elicit immunity directly in the airways as well as systemically. Building on pediatric parainfluenza virus vaccines in clinical development, we generated a live-attenuated parainfluenza-virus-vectored vaccine candidate expressing SARS-CoV-2 prefusion-stabilized spike (S) protein (B/HPIV3/S-6P) and evaluated its immunogenicity and protective efficacy in rhesus macaques. A single intranasal/intratracheal dose of B/HPIV3/S-6P induced strong S-specific airway mucosal immunoglobulin A (IgA) and IgG responses. High levels of S-specific antibodies were also induced in serum, which efficiently neutralized SARS-CoV-2 variants of concern of alpha, beta, and delta lineages, while their ability to neutralize Omicron sub-lineages was lower. Furthermore, B/HPIV3/S-6P induced robust systemic and pulmonary S-specific CD4+ and CD8+ T cell responses, including tissue-resident memory cells in the lungs. Following challenge, SARS-CoV-2 replication was undetectable in airways and lung tissues of immunized macaques. B/HPIV3/S-6P will be evaluated clinically as pediatric intranasal SARS-CoV-2/parainfluenza virus type 3 vaccine. © 2022
Authors & Co-Authors
Nelson, Christine E.
United States, Bethesda
National Institutes of Health Nih
Moore, Rashida M.
United States, Bethesda
National Institutes of Health Nih
Walker, April M.
United States, Bethesda
National Institutes of Health Nih
Lusso, Paolo
United States, Bethesda
National Institutes of Health Nih
Johnson, Reed F.
United States, Bethesda
National Institutes of Health Nih
Garza, Nicole L.
United States, Bethesda
National Institutes of Health Nih
Via, L. E.
United States, Bethesda
National Institutes of Health Nih
Barber, Daniel L.
United States, Bethesda
National Institutes of Health Nih
Buchholz, Ursula J.
United States, Bethesda
National Institutes of Health Nih
Statistics
Citations: 9
Authors: 9
Affiliations: 1
Identifiers
Doi:
10.1016/j.cell.2022.11.006
ISSN:
00928674